MARKET

SLNCF

SLNCF

Silence Therapeutics Plc
OTCPK
1.750
NaN%
Closed 09:30 03/05 EST
OPEN
--
PREV CLOSE
1.750
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
2.000
52 WEEK LOW
0.499
MARKET CAP
247.98M
P/E (TTM)
-3.2270
1D
5D
1M
3M
1Y
5Y
1D
Silence Therapeutics CEO Tooman to depart; Chairman Ross to lead on interim basis
Seeking Alpha · 12/15/2025 13:30
Silence Therapeutics plc Non-GAAP EPS of -$0.15, revenue of $0.16M
Seeking Alpha · 11/06/2025 16:11
Weekly Report: what happened at SLNCF last week (0908-0912)?
Weekly Report · 09/15/2025 09:42
Weekly Report: what happened at SLNCF last week (0901-0905)?
Weekly Report · 09/08/2025 09:44
Weekly Report: what happened at SLNCF last week (0825-0829)?
Weekly Report · 09/01/2025 09:42
Weekly Report: what happened at SLNCF last week (0818-0822)?
Weekly Report · 08/25/2025 09:45
Weekly Report: what happened at SLNCF last week (0811-0815)?
Weekly Report · 08/18/2025 09:43
Weekly Report: what happened at SLNCF last week (0804-0808)?
Weekly Report · 08/11/2025 09:45
More
About SLNCF
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Webull offers Silence Therapeutics plc stock information, including OTCPK: SLNCF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNCF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLNCF stock methods without spending real money on the virtual paper trading platform.